138 results about "Serotonin" patented technology

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses an application of a grape acetyl serotonin O-methyltransferase gene VvAST in induction of seedless, and a preparation method of the grape acetyl serotonin O-methyltransferase gene. Nucleotide sequences and amino acid sequences and specific applications are provided. The invention shows that overexpression of VvAST in tomato can significantly inhibit seed development and generate seedless phenotypes. Therefore, the VvAST can be used as a key molecular target for regulating and controlling the development of grape and tomato seeds, and has potential application value. Through gene editing or regulation and control of the expression level, stable and efficient seedless grape breeding is expected to be realized, and industrial development of high-quality seedless grape fruits is promoted.

The present invention aims to provide a method for evaluating the serotonin reuptake inhibitory effect of a composition containing valerian extract. [Solution] The present invention provides a method for evaluating antidepressant effects, which involves quantitatively analyzing one or more components contained in at least a part of a plant of the genus Valerian or a processed product thereof, and evaluating the antidepressant effect of the test substance by referring to the results of the quantitative analysis and criteria for antidepressant effect.

The present invention provides a compound which has a serotonin 5-HT2A receptor inverse agonist effect, a pharmaceutically acceptable salt thereof, and a composition which is for serotonin 5-HT2A receptor inverse agonism and which contains the compound or the salt. Provided is a composition which is for serotonin 5-HT2A receptor inverse agonism and which contains a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I) (In formula (I), R1 is a substituted or unsubstituted aromatic heterocyclic group or the like, each R2 is independently a hydrogen atom or the like, each R3 is independently a hydrogen atom or the like, n is 1 or 2, R4 is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group, L is -NR8- or the like, R8 is a hydrogen atom or the like, each R5 is independently a hydrogen atom or the like, each R6 is independently a hydrogen atom or the like, p is 1 or 2, and R7 is a group represented by the other formula shown.) (In the other formula shown, R9 is substituted or unsubstituted alkyloxy or the like, R10 is a hydrogen atom or the like, R11 is halogen or the like, and m is 0 or 1.)

Provided are a compound having serotonin 5-HT2A receptor antagonism and / or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and / or inverse agonism comprising them.A compound represented by Formula (I):wherein R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or the like; a combination of (L1, L2) is (NH, N) or the like; R4 is a group represented by Formula:wherein p and q are each independently 2 or the like; Ra is substituted or unsubstituted alkyl or the like; Xb is each independently CRbRb′; Rb is each independently a hydrogen atom or the like; Rb′ is each independently a hydrogen atom or the like; Xc is each independently CRcRc′; Rc is each independently a hydrogen atom or the like; Rc′ is each independently a hydrogen atom or the like; Xd is CRd or the like; and Rd is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; and R7 is a group represented by Formula:wherein A is CR11 or the like; R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; and R11 is each independently a hydrogen atom or the like; or a pharmaceutically acceptable salt thereof.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

Provided is a mutated promoter sequence. The mutated promoter sequence has a base mutation relative to a parent promoter. The parent promoter is a promoter derived from a tomato SlTDC1 gene. The mutated promoter sequence results in an increase in the content of serotonin in tomato fruits, possessing broad application prospects.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

The application discloses a method for differentiating stem cells into caudal serotonergic neurons, a complete culture medium and application. Specifically, a new culture medium is formed by adding small molecule compounds, so that human pluripotent stem cells are gradually induced to obtain hindbrain neural stem cells, ventral hindbrain caudal neural stem cells, serotonergic precursor cells and caudal serotonergic neurons of the hindbrain. The culture method is simple, and can efficiently obtain mature serotonergic neurons of specific regions, thereby providing an effective cell model for research on diseases related to the serotonergic system.

The purpose of the present disclosure is to provide a novel plant environmental stress alleviator, a plant growth promoter, and a plant DNA repair promoter that have an excellent effect of alleviating environmental stresses such as high temperatures.　The present disclosure provides a plant environmental stress alleviator, a plant growth promoter, and a plant DNA repair promoter containing: one or more neurotransmitters selected from choline esters, catecholamines, serotonin, and amino acids, and / or one or more acetylcholinesterase inhibitors selected from polyphenols, flavonoids, and organic acids, or a plant extract containing said inhibitors; and calcium ions. The present disclosure also provides a method for producing the aforementioned agents.

Provided herein are pharmaceutical compositions, kits comprising pharmaceutical compositions, methods of treating disease, and methods of making compositions. The pharmaceutical compositions described herein are powdery pharmaceutical compositions, which can contain encapsulated pharmaceutical agents, such as serotonin receptor agonists. The powdery pharmaceutical compositions may be administered by an inhaler device described herein.

This invention provides compounds having serotonin 5-HT2A receptor inverse agonist activity or pharmaceutically permissible salts thereof, and compositions for serotonin 5-HT2A receptor inverse agonist containing the like. The compositions for serotonin 5-HT2A receptor inverse agonist contain a compound represented by formula (I) or a pharmaceutically permissible salt thereof, wherein in formula (I), R... 1 It is a substituted or unsubstituted aromatic heterocyclic group, etc., R 2 Each is independently a hydrogen atom, etc., R 3 Each is independently a hydrogen atom, etc., n is 1 or 2, R 4 It is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group, and L is -NR. 8 - etc., R 8 It is a hydrogen atom, etc., R 5 Each is independently a hydrogen atom, etc., R 6 Each is independently a hydrogen atom, etc., p is 1 or 2, R 7 It is a basis expressed by the following formula, where R 9 It is a substituted or unsubstituted alkoxy group, etc., R 10 It is a hydrogen atom, etc., R 11 It is a halogen, etc., where m is 0 or 1.

The present invention relates to serotonin derivatives of general formula (I), and their use in the pharmaceutical field, in particular for preventing or treating metalloptosis associated disorders. The invention also relates to new serotonin derivatives of general formula (I) and their use for preventing or treating iron- and / or copper-associated disorders.

The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses, and central nervous system (CNS) disorders.

The present application relates to serotonin receptor agonists, including azepino compounds, as well as methods of using them for treating and preventing a variety of conditions.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

To provide a new lactic acid bacterium and its use.SOLUTION: The features of the present invention for solving the above problems are as follows. It is characterized in that it can be used for various health-promoting applications using lactic acid bacteria Lacticaseibacillusparacaseisp. Shidare (accession number NITEABP-04138). Specifically, this lactic acid bacterium is characterized by exhibiting various effects such as promotion of production of IgA, IL-10, IL-12, and serotonin, normalization of stool shape and improvement of bowel movement, improvement of feeling of incomplete evacuation, adjustment of intestinal environment, immunoregulatory action, promotion of equol production, and further, promotion of collagen gene and hyaluronic acid gene expression, and EMT suppression.SELECTED DRAWING: None

The invention relates to a high-serotonin-yield recombinant bacterium and application thereof, and belongs to the technical field of fermentation. According to the tryptamine-5-hydroxylase mutant disclosed by the invention, the enzyme activity of the tryptamine-5-hydroxylase mutant obtained by mutating glutamic acid at the 166th site of the tryptamine-5-hydroxylase into lysine and valine at the 220th site of the tryptamine-5-hydroxylase into glutamic acid is obviously improved, and meanwhile, the tryptamine-5-hydroxylase mutant also obviously improves the coupling efficiency of NADPH (the ratio of generated serotonin to consumed NADPH); the improvement of the coupling efficiency means that more serotonin can be synthesized under the condition of the same concentration of NADPH, so that the fermentation of the serotonin is facilitated. In addition, the synthesis of NADPH, the synthesis of L-tryptophan and the like are improved, the obtained recombinant bacteria can produce serotonin at high yield, and the fermentation cost of the serotonin can be reduced.

The invention relates to a method for promoting tobacco leaves to quickly generate serotonin, and belongs to the field of biotechnology and plant metabolic engineering.The method includes the steps that serotonin in walnuts is identified to synthesize key genes, cDNA of the key genes is used as a template to amplify target fragments, a pHREAC expression vector is constructed and then introduced into agrobacterium tumefaciens, and the serotonin is obtained; and injecting the bacterial liquid into the lower epidermis of the tobacco leaf by using a syringe without a needle head for transient expression. And high-efficiency expression of exogenous genes can be realized within 3-5 days. The method does not need a complex procedure of gene operation breeding, does not require stable expression of transgenosis, is simple and convenient to operate, short in period and high in efficiency, and is suitable for rapid development of functional components and plant metabolism engineering application.

The technical scheme provided by the invention is application of quercetin in aquaculture, in particular to application of quercetin in preparation of drugs and / or feeds for preventing and treating thyroxine disorder and / or serotonin disorder of aquatic animals. The invention has the beneficial technical effects that the natural plant component quercetin which is originally applied to medicines and health care products for people is expanded to be applied to the field of aquatic animals, so that the nutrition required by the aquatic animals can be provided, the effect of regulating thyroid hormone and / or serotonin disorder of the aquatic animals can be achieved, the quercetin is used for replacing hormone medicines, and the health care effect is good. The method is friendly to an ecological chain, and green, cyclic and sustainable development is realized.

Provided are compounds having a serotonin 5-HT2A receptor inverse agonism, pharmaceutically acceptable salts thereof, and a composition comprising them,A composition comprising the compounds of Formula (I):or pharmaceutically acceptable salts thereof,wherein: R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or 2; R4 is substituted or unsubstituted non-aromatic nitrogen-containing heterocyclyl or the like; L is —NR8— or the like; R8 is a hydrogen atom or the like; R5 is each independently a hydrogen atom or the like; R6 is each independently a hydrogen atom or the like; p is 1 or 2; and R7 is a group represented by Formula:wherein R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; R11 is halogen or the like; and m is 0 or 1.

This invention relates to the application of a traditional Chinese medicine composition in the preparation of a drug for neurogenic headache. The composition is characterized by being prepared from Rehmannia glutinosa (processed), Cornus officinalis, Dioscorea opposita, Alisma plantago-aquatica, Paeonia suffruticosa, and Poria cocos. The composition significantly reduces the number of head scratches in rats with nitroglycerin-induced neurogenic headache, decreases the levels of neurogenic headache-related factors (NO, CGRP) in plasma, improves reserpine-induced low serotonin (5-HT) symptoms in mice, and increases clotting time, suggesting that this traditional Chinese medicine composition has a good therapeutic effect on neurogenic headache.

The amisulpride derivatives and the R enantiomer of amisulpride, or pharmaceutical compositions thereof, disclosed herein can be used alone or in combination with other CNS active agents to antagonize serotonin (e.g., 5-HT2a, 5-HT7) receptors in a subject. The amisulpride derivatives and the R enantiomer of amisulpride, or pharmaceutical compositions thereof, disclosed herein can be used alone or in combination with other CNS active agents to treat one or more conditions responsive to modulation of serotonin (e.g., 5-HT2a, 5-HT7) receptors in a subject. The amisulpride derivatives and the R enantiomer of amisulpride, or pharmaceutical compositions thereof, disclosed herein can be used alone or in combination with other CNS active agents to treat one or more disorders associated with abnormal levels of serotonin in the brain.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

The present application provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a serotonergic psychedelic drug and a therapeutically effective amount of a phosphodiesterase type 9 inhibitor.

The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II): or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, modulation of 5-hydroxytryptamine (5-HT) receptor subtypes, including 5-hydroxytryptamine 2A receptor and / or 5-hydroxytryptamine 2C receptor, and treatment of a condition or disease where the treatment is associated with the modulation of 5-hydroxytryptamine 2A receptor and / or 5-hydroxytryptamine 2C receptor.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as selective agonists or antagonists serotonin (5-HT2A) receptor, preferably non-hallucinogenic biased agonists or antagonists at the serotonin (5-HT2A) receptor, such as having agonism biased towards the beta-arrestin signaling pathway, or as serotonin (5-HT2A) receptor antagonists. Such compounds are useful for the treatment of mood disorders, general anxiety, social anxiety, depression, anhedonia, and other neuropsychiatric diseases.

Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of using them for treating and preventing addictions and overdoses.